Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate Cancer

被引：2
|
作者：
Rezvani, Hamid [1 ]
Ghadyani, Shirin Haghighi Mojtaba [1 ]
Attarian, Hamid [1 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Taleghani Hosp, Tehran, Iran
来源：
UROLOGY JOURNAL | 2012年 / 9卷 / 04期
关键词：
prostatic neoplasms; treatment failure; antineoplastic agents; drug resistance; PHASE-II TRIAL; MITOXANTRONE PLUS PREDNISONE; CLINICAL-TRIALS; WORKING GROUP; DOCETAXEL; ANGIOGENESIS; RECOMMENDATIONS; GUIDELINES; INHIBITOR; REGISTRY;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose: To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer. Materials and Methods: This clinical trial was performed on 16 patients with hormone-resistant prostate cancer. Results: Mean age of the participants was 72.7 +/- 5.39 years (range, 65 to 85 years). In 94% of patients who received the drug combination, prostate-specific antigen level decreased more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy had some adverse events. Conclusion: Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients.
引用
收藏
页码：673 / 677
页数：5
相关论文
共 50 条
  • [1] Value of mitoxantrone in hormone-resistant metastatic prostate cancer.
    Khalaf, A
    Pfister, C
    Hellot, MF
    Dunet, F
    Moussu, J
    Grise, P
    PROGRES EN UROLOGIE, 2002, 12 (01): : 37 - 42
  • [2] Hormone-resistant prostate cancer
    Khoury, S
    PROGRES EN UROLOGIE, 2002, 12 (01): : 7 - 18
  • [3] Value of mitoxantrone in hormone-resistant metastatic prostate cancer - Commentary
    Coulange, C
    PROGRES EN UROLOGIE, 2002, 12 (01): : 41 - 41
  • [4] Role of mitoxantrone in the management of hormone-resistant metastatic prostate cancer
    Culine, S
    PROGRES EN UROLOGIE, 2002, 12 (01): : 31 - 35
  • [5] Weekly epirubicin in patients with hormone-resistant prostate cancer
    Petrioli, R
    Fiaschi, AL
    Pozzessere, D
    Messinese, S
    Sabatino, M
    Marsili, S
    Correale, P
    Manganelli, A
    Salvestrini, F
    Francini, G
    BRITISH JOURNAL OF CANCER, 2002, 87 (07) : 720 - 725
  • [6] Introduction - Hormone-resistant prostate cancer
    Coulange, C
    Khoury, S
    PROGRES EN UROLOGIE, 2002, 12 (01): : 5 - 5
  • [7] Weekly epirubicin in patients with hormone-resistant prostate cancer
    R Petrioli
    A I Fiaschi
    D Pozzessere
    S Messinese
    M Sabatino
    S Marsili
    P Correale
    A Manganelli
    F Salvestrini
    G Francini
    British Journal of Cancer, 2002, 87 : 720 - 725
  • [8] Pathophysiology of hormone-resistant prostate cancer
    Belev, Borislav
    Sipic, Tomislav
    PERIODICUM BIOLOGORUM, 2014, 116 (04) : 387 - 392
  • [9] Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel
    Gasent, J. M.
    Grande, E.
    Casinello, J.
    Provencio, M.
    Laforga, J. B.
    Alberola, V.
    ACTAS UROLOGICAS ESPANOLAS, 2011, 35 (01): : 57 - 60
  • [10] WEEKLY LOW-DOSE ADRIAMYCIN IN HORMONE-RESISTANT METASTATIC CANCER OF THE PROSTATE
    FOSSA, SD
    URNES, T
    KAALHUS, O
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1987, 21 (01): : 13 - 16
12345